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ABSTRACT: In this report we present a method to
identify functional artiﬁcial lantipeptides. In vitro trans-
lation coupled with an enzyme-free protocol for
posttranslational modiﬁcation allows preparation of more
than 1011 diﬀerent lanthionine containing peptides. This
diversity can be searched for functional molecules using
mRNA-lantipeptide display. We validated this approach by
isolating binders toward Sortase A, a transamidase which is
required for virulence of Staphylococcus aureus.T h e
interaction of selected lantipeptides with Sortase A is
highly dependent on the presence of a (2S,6R)-lanthionine
in the peptide and an active conformation of the protein.
L
antipeptides are produced by a range of Gram-positive
bacteria and are often characterized by potent antibacterial
activities.
1−3 The peptide scaﬀold is ﬁrst assembled by
ribosomal translation and later acquires a series of post-
translational modiﬁcations which support the bioactive
conformation of the molecule. The most notable modiﬁcations
are the dehydration of serine and threonine residues and the
formation of lanthionine moieties (Lan) by intramolecular 1,4-
addition of Cys side chains onto dehydroamino acids. These
modiﬁcations are introduced by lantipeptide dehydratases and
cyclases, which are characterized by surprisingly broad substrate
scopes.
4−8 Since the primary sequences of lantipeptides are
genetically encoded, this class of natural products is amenable
to directed molecular evolution and thus appears to be an
excellent platform for the development of therapeutic
molecules. In addition, heterologous production of both native
and engineered lantipeptides
9,10 has shown that such
compounds should be accessible on useful scales despite their
size and complex structures.
In the quest for therapeutic peptides over 50 natural
lantipeptides have been described,
1−3 and many more artiﬁcial
Lan-containing peptides have been constructed,
5,7,11−16 but a
systematic method for identifying lantipeptides with tailor-
made functions is missing. We therefore developed an in vitro
selection method for the production and parallel screening of
up to 1011 diﬀerent lantipeptides. The key to this method is a
protocol which allows in vitro translation of cross-linked
peptides,
11,17 which are linked to their coding mRNA (Figure
1).
18,19 This phenotype-genotype linkage allows enrichment of
rare sequences based on the functionality of their encoded and
posttranslationally modiﬁed peptide. We then used solid phase
peptide synthesis (SPPS) and in vitro characterization of
selected lantipeptides to demonstrate that this method
produces highly Lan-speciﬁc molecular interactions.
In order to prepare Lan-containing peptides we used a
chemically deﬁned translation mixture in which we substituted
lysine with 4-selenalysine.
11,17,20 This unnatural amino acid is
amenable to H2O2 induced post-translational elimination to
dehydroalanine (Dha). As a template for peptide synthesis we
used in vitro transcribed mRNA which was photo-cross-linked
to a short puromycin-displaying oligonucleotide at the 3′-end of
the open reading frame (Figure 1). This tag causes the
ribosome to form a covalent bond between the C-terminus of
the nascent peptide and the templating mRNA strand (Figure
1).
19 The resulting peptide-mRNA fusions were immobilized
on oligo-dT Sepharose under high salt conditions through base
complementarity to a stretch of adenine bases on the mRNA.
The immobilized fusions were then treated with a sequence of
buﬀers to induce the formation of Lan moieties (Figure 2).
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Figure 1. Formation of mRNA-displayed lantipeptides. (a) Tran-
scription from a synthetic DNA library coding for peptides with a
conserved Lys-X2-Cys motif; (b) attachment of a puromycin (P)
labeled oligonucleotide by photo-cross-linking; (c) ribosomal peptide
synthesis in a reconstituted translation system, in which lysine was
substituted with 4-selenalysine; (d) mRNA-peptide fusions were
immobilized on oligo-dT sepharose and chemically treated to
introduce Lan cross-links; (e) reverse transcription and NTA-agarose
puriﬁcation of the ﬁnal mRNA-peptide fusions; (f) in vitro selection:
the pool of 20 pmol of fusions was incubated with immobilized Sortase
A SrtA; (g) retained mRNA messages were PCR ampliﬁed to serve as
the DNA template for the next selection round.
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the very small quantity of fragile molecules such as picomoles of
peptide-mRNA fusions.
To evaluate the eﬃciency of this step we constructed an
mRNA template coding for a peptide containing two Lys-
X2-LCys motifs. The corresponding 35S-methionine labeled
peptide-mRNA fusions were immobilized on oligo dT
sepharose and modiﬁed as outlined in Figure 2. 35S-Met
scintillation counting suggested that 70% of the fusions are
retained throughout the modiﬁcation procedure (Figure S1),
and MALDI-TOF spectrometry of the peptide portion showed
that the two Lys-X2-LCys motifs have indeed been converted to
Lan moieties (Figure S1).
Next, we constructed a double stranded DNA library coding
for one conserved Lys-X2-Cys motif along with seven additional
random residues (X) and a C-terminal histidine tag (Figure 2).
In addition we included three conserved Arg residues ﬂanking
the random region to improve peptide solubility even in the
absence of the mRNA tail. The codons for the conserved Val-
Glu dipeptide provide two stop codons which terminate the
translation of sequences with a frameshift. From this library we
transcribed 1 nmol of puromycin tagged mRNA and subjected
this pool to a 2.5 mL translation reaction.
17,18,20 After
introduction of the Lan moieties, the fusions were eluted
from the sepharose support. Reverse transcription and
puriﬁcation on NTA agarose yielded an initial pool of 20
pmol of mRNA peptide fusions as inferred by 35S-Met
scintillation counting. This corresponds to 1.2 × 1013
molecules, providing 24-fold coverage of the 5 × 1011 diﬀerent
sequences.
With this pool of mRNA-displayed artiﬁcial lantipeptides
available, we set out to identify speciﬁc binders to Sortase A
(SrtA) from Staphylococcus aureus (S. aureus).
22 This Cys-
dependent transamidase anchors extracellular virulence factors
to the growing cell wall. The enzyme recognizes a Leu-Pro-X-
Thr-Gly motif on precursor proteins, cleaves the amide bond
between Thr and Gly, and links Thr with the penta-Gly tail of
the cell wall precursor lipid II.
22 Similar enzymes are ubiquitous
among gram positive bacteria and may therefore present a
target for broad-band antibacterials.
23 However, development
of eﬀective low molecular weight inhibitors has proven to be
diﬃcult.
23−28 This challenge coupled with the well-behaved
nature of the catalytic domain of SrtA makes this protein an
ideal test case for a ﬁrst in vitro selection of artiﬁcial
lantipeptides (Figure S2).
We immobilized 1 nmol of biotinylated SrtA on streptavidin-
coated beads and coincubated with the 20 pmol pool of
mRNA-displayed lantipeptides for 1 h. The beads were washed
to remove approximately 98% of the speciﬁc 35S-Met activity.
The retained nucleic acids were eluted in 100 mM NaOH and
ampliﬁed by PCR. The product DNA was used as a template to
generate a new mRNA pool for the next selection round. To
suppress coselection of peptides which bind to the streptavidin-
coated beads rather than to SrtA, we used a slightly diﬀerent
protocol for the next four rounds: we eluted speciﬁc SrtA
binders by incubating the beads in a 0.2 mM solution of soluble
SrtA for 2 h. Enrichment of SrtA binders was monitored in each
round by quantifying the fraction of the pool retained by the
SrtA-coated beads after a standardized washing protocol
(Figure S3). In round ﬁve, 25% of the fusions bound to
immobilized SrtA suggesting that a signiﬁcant portion of this
pool codes for SrtA-binding mRNA-peptide fusions. Since this
fraction did not increase after an additional selection round, we
cloned and sequenced individual members of the pool after
round ﬁve.
From 42 clones we retrieved 36 sequences which coded for a
central Lys-X2-LCys motif as designed in the initial library.
These peptides are characterized by mainly hydrophobic
residues with a particular overrepresentation of Trp. While
the N-terminus of the randomized segment features a
conserved Leu-Trp dipeptide, the C-terminus is more variable
and splits the sequences into two families represented by the
sequences 2 to 6 and 7 to 10 (Table 1, Figure S4).
Since in vitro translation does not provide enough material to
verify peptide structure and function we picked nine selected
sequences and prepared the corresponding peptides with a C-
terminal polyethylenglycol (peg) tail
21 by standard Fmoc-SPPS
(Table 1). In a biomimetic approach,
29−33 we ﬁrst synthesized
linear peptides containing a Dha-X2-LCys motif (Figures S5, S6
and Table S2) which cyclized after puriﬁcation upon raising the
pH above 8.0. Cyclization produced the (2S,6R)-Lan and
(2R,6R)-Lan containing peptides with a signiﬁcant excess of
one isomer (60−80% de). Dha-X2-LCys motifs are known to
preferentially form the (2S,6R)-Lan irrespective of the
remaining peptide context.
30−33 To conﬁrm the predicted
stereochemistry we resynthesized peptide 2 replacing the Dha-
X2-LCys motif with a DCys-X2-Dha or LCys-X2-Dha motif. The
latter two motifs are predicted to cyclize stereorandomly to
mixtures of (2S,6S)-Lan and (2S,6R)-Lan or (2R,6S)-Lan and
(2R,6R)-Lan containing molecules (2(2S,6S), 2(2S,6R), 2(2R,6S), and
2(2R,6R)).
34 Despite the changes in their initial sequence, the
four cyclic isomers diﬀer only by one or two stereocenters. By
HPLC comparison of the three cyclization reactions each
containing a diﬀerent pair of isomers, we were able to assign the
stereochemistry of all four possible isomers and conﬁrmed the
major cyclization product arising from the Dha-X2-LCys motif
as the (2S,6R)-Lan isomer (Figure S7).
Binding aﬃnities were measured by ﬂuorescence polarization
using ﬂuorescein-labeled versions of all four isomers of 2
(Figure S8). Only 2(2S,6R) binds to SrtA, with a Kd of 3 ± 0.2
μM, whereas all other isomers fail to exhibit detectable binding
aﬃnity (Table 1). Also, the linear version of 2(2S,6R) in which
Figure 2. (Top) Enzyme-free Lan formation.
11 (1) Translated
peptides were incubated with oxidized glutathione (GSHox) to protect
Cys residues from irreversible oxidative damage; (2) H2O2 induced
oxidative elimination of 4-selenalysine to Dha; (3) disulﬁde reduction
initiated intramolecular 1,4-addition of Cys side chains onto Dha to
produce Lan-containing peptides (TCEP: tris(2-carboxyethyl)-
phosphine). (Bottom) In gray: constant regions. (P): puromycin
links the peptide with its coding mRNA. peg: the C-terminus of
synthetic peptides was appended with a polyethylenglycol tail to
increase solubility.
21 5-FAM: 5-carboxyﬂuorescein. Lan: the two
thioether-bridged residues are labeled as Lan.
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(2linear) does not bind to SrtA either (Table 1). In addition,
2(2S,6R) has no detectable aﬃnity to SrtB, a staphylococcal
homologue of SrtA with similar biological functions but only
22% sequence similarity.
35 We also prepared 2(2S,6R) without
peg-tail. This peptide binds SrtA with a similar aﬃnity as
2(2S,6R), suggesting that this tail does not contribute to the
observed binding (no peg, Table 1).
SrtA depends on millimolar concentrations of Ca2+ for
eﬃcient substrate recognition.
36 This cation does not contact
the substrate directly but rather immobilizes two active site
loops by coordinating several of their carboxylate side chains.
Binding of 2(2S,6R) is similarly Ca2+ dependent, suggesting that
its binding site overlaps with the SrtA active site. Regardless,
2(2S,6R) at a concentration of up to 1 mM is unable to inhibit
SrtA catalyzed cleavage of a peptide substrate, even though this
reaction is characterized by a relatively high Km of 80 μM (data
not shown). However, if kcat is faster than dissociation of the
substrate/enzyme complex (koﬀ), the substrate aﬃnity could be
signiﬁcantly higher than indicated by Km (koﬀ/kon ≪ kcat/kon),
making it impossible for 2(2S,6R) to compete for binding.
Finally, we determined the aﬃnities of peptides 3(2S,6R) to
10(2S,6R) (Table 1). Most members of family 1 (2(2S,6R) to
6(2S,6R)) bind SrtA with a Kd ranging from 3 to 11 μM (Figure
S4). As an outlier, 6(2S,6R) is a 10-fold weaker binder than 2(2S,6R)
as the result of a Ser to Thr mutation in the lanthionine
macrocycle. None of the corresponding (2R,6R)-Lan contain-
ing peptides showed detectable aﬃnity for SrtA (Kd > 200 μM).
Again, the Lan induced macrocycle appears crucial for the
observed binding activity and represents a novel scaﬀold
amenable to optimization by chemical derivatization. Neither
isomer of the second family (7 to 10, Table 1) recognizes SrtA,
suggesting that these sequences emerged by way of an
alternative selective pressure.
The method outlined in this communication allows the
identiﬁcation of functional molecules from a random pool of
artiﬁcial lantipeptides. In a ﬁrst demonstration we found
molecules with highly speciﬁca ﬃnities toward a potential drug
target from S. aureus. Unlike other peptide cyclization
protocols
37−40 Lan formation oﬀers alterations in the backbone
stereochemistry in addition to conformational rigidity. Natural
lantipeptides generally contain (2S,6R)-Lan due to enzyme
imposed stereocontrol. In contrast, enzyme-free introduction of
Lan can access (2S,6R)-Lan, (2R,6R)-Lan, and (2R,6S)-Lan
containing molecules which may compete for function during
in vitro selection. As shown here, deconvolution of the
stereochemical information after in vitro selection is relatively
straightforward, using a biomimetic approach to SPPS of
lantipeptides. Therefore we conclude that the herein presented
method should allow a search for functional lantipeptides in
both sequence and geometry space.
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